Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07051915 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Holistic Study

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2025 to Sep 15, 2025
    • Collaborators: 13 to 11
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Trial Details
NCT Number NCT07051915
Lead Sponsor Ostfold Hospital Trust
Collaborators: Oslo University Hospital, University Hospital, Akershus, Sykehuset i Vestfold HF, St. Olavs Hospital, Helse Stavanger HF, Sorlandet Hospital HF, University Hospital of North Norway, Haukeland University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Nordlandssykehuset HF
Conditions
(from sponsor)		 Thrombocytopenia Purpura
Related terms Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov